Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of IGNG 5% in primary immunodeficiency
2009-012036-32Phase 3Active
- Sponsor
- LFB Group
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in Immunogenetic disorder, sponsored by LFB Group. Primary endpoint: Number of infusions and proportion with IMP-related adverse events by highest flow rate. Started May 2009; status: active.
02
Drugs
subcuvia
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2009-012036-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012036-32.